Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CZMWF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CZMWF and 80,000+ other tickers.
See exactly how CZMWF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CZMWF and 80,000+ other tickers.
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment…
Carl Zeiss Meditec AG (CZMWY) Q2 2026 Earnings Call Transcript
Carl Zeiss Meditec ETR: AFX reported weaker first-half results for fiscal 2025/2026 and outlined a broad restructuring plan aimed at restoring profitability over the next three years, as management pointed to currency headwinds, soft equipment demand and pressure in China's intraocular lens business.
Carl Zeiss Meditec AG is rated a "Buy" despite recent operational weakness and geopolitical headwinds, especially in Asia-Pacific and North America. Sales declined 4.8% in Q1, with margin compression and a suspended 2025/2026 outlook due to weak demand across Asia-Pacific and North America. CZMWF now trades at a significant discount to peers, with a 2026 price target of $39.26, implying ~20% upside against a discounted multiple.
Carl Zeiss Meditec AG (CZMWY) Q1 2026 Earnings Call Transcript
Carl Zeiss Meditec is rated a 'Strong Buy' with higher share price target, reflecting significant undervaluation and robust fundamentals. The company achieved over €2.2B in revenue (+7.5% YoY), strong order backlog, and over 50% recurring revenue, enhancing earnings stability. Despite Chinese market headwinds and low yield (1.3%), the company's vertical integration, innovation, and market leadership support a premium valuation.